Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. Impel Pharmaceuticals Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.

Impel Pharmaceuticals Inc.

Impel Pharmaceuticals is focused on developing and providing transformative therapies for people suffering from diseases with high unmet needs across various disease areas in addition to the central nervous system (CNS), through the pioneering of an optimized approach to drug delivery. We offer and develop treatments that pair the Company’s proprietary Precision Olfactory Delivery (POD®) technology with well-established therapeutics. 

Impel Pharmaceuticals

Summer is a tough time of year for #migraine and #headaches. To best celebrate #freedom with your friends and family, be mindful of your triggers and keep your acute meds on hand.
 
Wishing everyone a safe and happy #IndependenceDay!

Trudhesa® (DHE mesylate) delivers a trusted #migraine therapeutic to the vascular-rich upper nasal space via the POD® device developed by our co-founder, CTO & CDO, John Hoekman. This results in IV-like efficacy at home - not via injection in an ER.

The Impel team proudly supports the #migraine community. Today we're wearing our #ShadesForMigraine to raise awareness about this complex, neurological disease that's more than just a #headache. 

#MHAM #MigraineAwareness

A second poster on preliminary real-world data underscores the need for non-oral treatment options for #migraine given the prevalence of pre-existing #gastrointestinal disorders among those prescribed with Trudhesa® (DHE mesylate).

See abstract P-160 in Headache: https://lnkd.in/eV8n_mNw

Read our press release to learn more: https://lnkd.in/eEkwReSh

#MHAM Dr. Sheena Aurora

Preliminary real-world data at #AHSAM suggest that concomitant preventive & acute medication use generally decreases in patients taking Trudhesa® (DHE mesylate) nasal spray, and that use of antinausea medications (common with DHE administered via IV) did not increase.

See abstract P-161 in Headache: https://lnkd.in/eV8n_mNw

Read yesterday's press release to learn more: https://lnkd.in/eEkwReSh 

#Migraine #MHAM Zubair Ahmed

	Dec '19	Dec '20	Dec '21	Dec '22
net income	-41.86M -	-45.80M 9.41%	-76.54M 67.12%	-106.31M 38.90%
depreciation and amortization	722K -	1.08M 49.17%	1.09M 1.02%	1.20M 10.39%
deferred income tax		153K -	2.13M 1,294.12%
stock based compensation	794K -	3.64M 358.56%	3.13M 14.03%	5.19M 65.85%
change in working capital	3.21M -	1.54M 52.21%	2.21M 44.14%	-13.01M 687.49%
accounts receivables			-1.35M -	-6.09M 350.59%
inventory			-3.02M -	-5.75M 90.31%
accounts payables	1.42M -	1.50M 5.20%	2.00M 33.44%	-275K 113.76%
other working capital	1.79M -	38K 97.88%	4.59M 11,978.95%	-887K 119.32%
other non cash items	642K -	208K 67.60%	1.61M 672.60%	19.29M 1,100.06%
net cash provided by operating activities	-36.49M -	-39.18M 7.39%	-66.36M 69.37%	-93.64M 41.10%
investments in property plant and equipment	-1.52M -	-1.78M 17.01%	-408K 77.10%	-1.38M 237.50%
acquisitions net
purchases of investments
sales maturities of investments
other investing activites
net cash used for investing activites	-1.52M -	-1.78M 17.01%	-408K 77.10%	-1.38M 237.50%
debt repayment		-1.10M -		-32.85M -
common stock issued			120.31M -	4.25M 96.47%
common stock repurchased
dividends paid
other financing activites	21K -	12.16M 57,800%	27.58M 126.79%	96.06M 248.35%
net cash used provided by financing activities	21K -	11.06M 52,561.90%	147.89M 1,237.27%	67.46M 54.38%
effect of forex changes on cash
net change in cash	-37.99M -	-29.91M 21.28%	81.12M 371.24%	-27.56M 133.97%
cash at beginning of period	74.99M -	37.00M 50.66%	7.09M 80.82%	88.21M 1,143.30%
cash at end of period	37.00M -	7.09M 80.82%	88.21M 1,143.30%	60.65M 31.24%
operating cash flow	-36.49M -	-39.18M 7.39%	-66.36M 69.37%	-93.64M 41.10%
capital expenditure	-1.52M -	-1.78M 17.01%	-408K 77.10%	-1.38M 237.50%
free cash flow	-38.01M -	-40.97M 7.77%	-66.77M 63.00%	-95.02M 42.30%

COM:IMPELPHARMA

Impel Pharmaceuticals Inc.

Last Close

0.06

20/12 20:58

Market Cap

956K

Beta: -

Volume Today

720.03K

Avg: -

Preview